Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Risankizumab may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Skyrizi contains the active substance risankizumab. Skyrizi is used to treat patients 16 years and older with moderate to severe Crohn's disease and adults with moderate to severe ulcerative colitis. How Skyrizi works This medicine works by stopping a protein in the body called 'IL-23', which causes inflammation. Crohn's disease Crohn's disease is an inflammatory disease of the digestive tract. If you have active Crohn's disease you will first be given other medicines. If these medicines do not work well enough, you will be given Skyrizi to treat your Crohn's disease. Ulcerative colitis Ulcerative colitis is an inflammatory disease of the large bowel. If you have active ulcerative colitis you will first be given other medicines. If these medicines do not work well enough or if you cannot take these medicines, you will be given Skyrizi to treat your ulcerative colitis. Skyrizi reduces the inflammation and can therefore help to reduce the signs and symptoms of your disease. 2.
e Skyrizi
Do not use Skyrizi • if you are allergic to risankizumab or any of the other ingredients of this medicine (listed in section 6). 1
•
if you have an infection, including active tuberculosis, which your doctor thinks is important.
Warnings and precautions Talk to your doctor, pharmacist or nurse before and during the use of Skyrizi • if you currently have an infection or if you have an infection that keeps coming back. • if you have tuberculosis (TB). • if you have recently received or plan to receive an immunisation (vaccine). You should not be given certain types of vaccines while using Skyrizi. It is important to keep a record of the batch number of your Skyrizi. Every time you get a new pack of Skyrizi, note down the date and the batch number (which is on the packaging after "Lot") and keep this information in a safe place. Serious allergic reactions Skyrizi can cause serious side effects, including serious allergic reactions ('anaphylaxis'). Tell your doctor or seek medical help immediately if you notice any signs of an allergic reaction while you are taking Skyrizi such as: • difficulty breathing or swallowing • swelling of the face, lips, tongue or throat • low blood pressure, which can cause dizziness or light-headedness • severe itching of the skin, with a red rash or raised bumps Children and adolescents Skyrizi is not recommended for children and adolescents under 16 years of age. This is because Skyrizi has not been studied in this age group. Other medicines and Skyrizi Tell your doctor, pharmacist or nurse • if you are using, have recently used or might use any other medicines. • if you have recently had or are going to have a vaccination. You should not be given certain types of vaccines while using Skyrizi. If you are not sure, talk to your doctor, pharmacist or nurse before and during the use of Skyrizi. Pregnancy, contraception and breast-feeding If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. This is because it is not known how this medicine will affect the baby. If you are a woman who can become pregnant, you should use contraception while using this medicine and for at least 21 weeks after your last dose of Skyrizi. If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine. Driving and using machines Skyrizi is not likely to affect your driving and use of machines. Skyrizi contains polysorbate and sodium This medicine contains 0.24 mg of polysorbate 20 in each 180 mg dose and 0.48 mg of polysorbate 20 in each 360 mg dose. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies. This medicine contains less than 1 mmol sodium (23 mg) per cartridge, that is to say essentially 'sodium-free'.
2
3.
Skyrizi
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. This medicine is given as an injection under your skin (called a 'subcutaneous injection'). How much Skyrizi to use You will begin treatment with Skyrizi with a starting dose which will be given by your doctor or nurse through a drip in your arm (intravenous infusion). Starting doses Crohn's disease
Ulcerative colitis
How much? 600 mg 600 mg 600 mg
When? When your doctor tells you 4 weeks after 1st dose 4 weeks after 2nd dose
How much? 1 200 mg 1 200 mg 1 200 mg
When? When your doctor tells you 4 weeks after 1st dose 4 weeks after 2nd dose
Afterwards, you will receive Skyrizi as an injection under your skin. Maintenance doses Crohn's disease
Ulcerative colitis
How much? 1st maintenance dose
360 mg
Further doses
360 mg
How much? 1st maintenance dose
When? 180 mg or 360 mg 4 weeks after the last starting dose (at week 12) 180 mg or 360 mg Every 8 weeks, starting after the 1st maintenance dose
Further doses
When? 4 weeks after the last starting dose (at week 12) Every 8 weeks, starting after the 1st maintenance dose
You and your doctor, pharmacist or nurse will decide if you should inject this medicine yourself. Do not inject yourself with this medicine unless you have been trained by your doctor, pharmacist or nurse. A caregiver may also give your injection after they have been trained. Read section 7 'Instructions for use' at the end of this leaflet before injecting Skyrizi yourself. If you use more Skyrizi than you should If you have used more Skyrizi than you should or the dose has been given sooner than prescribed, talk to your doctor. If you forget to use Skyrizi If you forget to use Skyrizi, inject a dose as soon as you remember. Talk to your doctor if you are not sure what to do. If you stop using Skyrizi Do not stop using Skyrizi without talking to your doctor first. If you stop treatment, your symptoms may come back.
3
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious side effects Allergic reactions – these may need urgent treatment. Tell your doctor or get emergency medical help straight away if you notice any of the following signs: Serious allergic reactions ('anaphylaxis') are rare in people taking Skyrizi (may affect up to 1 in a 1 000 people). Signs include: • • •
difficulty breathing or swallowing swelling of the face, lips, tongue or throat low blood pressure, which can cause dizziness or light-headedness
Talk to your doctor or get medical help immediately if you have the following symptoms. Symptoms of a serious infection such as: • fever, flu-like symptoms, night sweats • feeling tired or short of breath, cough which will not go away • warm, red and painful skin, or a painful skin rash with blisters Your doctor will decide if you can keep using Skyrizi. Other side effects Tell your doctor, pharmacist or nurse if you get any of the following side effects Very common: may affect more than 1 in 10 people • upper respiratory infections with symptoms such as sore throat and stuffy nose Common: may affect up to 1 in 10 people • feeling tired • fungal skin infection • injection site reactions (such as redness or pain) • itching • headache • rash • eczema Uncommon: may affect up to 1 in 100 people • small raised red bumps on the skin • hives (urticaria) Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
4
5.
Skyrizi
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the cartridge label and outer carton after 'EXP'. Store in a refrigerator (2°C – 8°C). Do not freeze. If needed, you may also store the cartridge out of the refrigerator (up to a maximum of 25°C) for up to 24 hours. Keep the cartridge in the original carton in order to protect from light. Do not use this medicine if the liquid is cloudy or contains flakes or large particles. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Skyrizi contains The active substance is risankizumab. Skyrizi 180 mg solution for injection in cartridge Each cartridge contains 180 mg of risankizumab in 1.2 mL solution. The other ingredients are sodium acetate trihydrate, acetic acid, trehalose dihydrate, polysorbate 20 and water for injections. See section 2, "Skyrizi contains polysorbate and sodium". Skyrizi 360 mg solution for injection in cartridge Each cartridge contains 360 mg of risankizumab in 2.4 mL solution (150 mg/mL). The other ingredients are sodium acetate trihydrate, acetic acid, trehalose dihydrate, polysorbate 20 and water for injections. See section 2, "Skyrizi contains polysorbate and sodium".
–
What Skyrizi looks like and contents of the pack Skyrizi is a clear and colourless to yellow liquid in a cartridge. The liquid may contain tiny white or clear particles. Each pack contains 1 cartridge and 1 on-body injector. Marketing Authorisation Holder AbbVie Ltd Maidenhead SL6 4UB UK Tel: +44 (0)1628 561090 Manufacturer AbbVie Deutschland GmbH & Co. KG Knollstrasse 67061 Ludwigshafen 5
Germany This leaflet was last revised in 12/2025
To listen to or request a copy of this leaflet in Braille, large print or audio, please contact the Marketing Authorisation Holder. 7.
Instructions for use
Please read all of section 7 before using Skyrizi Skyrizi on-body injector Front view Adhesive material
Grey door Do not close grey door without cartridge inside
Status light
Medicine window
Back view Clear plastic strip Needle cover
Start button Do not touch until ready to inject
Pull tabs
Adhesive backing
6
Take care. Needle inside (under needle cover) Do not touch the needle cover area or needle
Small section green pull tab
Large section green pull tab
Side view Door latch Opening side has ridges Grey door should be slightly open Do not close grey door without cartridge inside Needle cover Needle inside (under needle cover) Do not touch the needle cover area or needle
7
Cartridge
Larger cartridge top Do not twist or remove
White plunger expands through chamber towards cartridge bottom as the medicine is injected.
Expiration date (EXP) Located on cartridge label
Medicine
Smaller bottom tip Important information to know before you inject Skyrizi • Store in a refrigerator (2°C – 8°C). Do not freeze. • Keep the cartridge in the original carton in order to protect from light. • You should receive training on how to inject Skyrizi before giving an injection. Talk to your doctor, pharmacist or nurse if you need help • Mark the dates on your calendar so you know when to inject Skyrizi • The single use on-body injector is designed for use with Skyrizi cartridge only • Keep Skyrizi in the original carton to protect the medicine from light until it is time to use it • Take the carton out of the refrigerator and leave it at room temperature, out of direct sunlight, for at least 45 up to 90 minutes before injecting o The on-body injector will not work if Skyrizi is not left at room temperature to warm for at least 45 minutes • Do not let the on-body injector get wet with water or any other liquids • Do not touch the start button until you place the on-body injector loaded with the cartridge onto your skin and are ready to inject o You can only press the start button one time • Physical activity should be limited during the injection process. Moderate physical activities can be done, such as walking, reaching and bending • Do not delay in injecting the medicine after loading the cleaned cartridge into the on-body injector. Waiting will dry out the medicine and the on-body injector will not work afterwards • Do not inject if the liquid in the inspection window is cloudy or contains flakes or large particles. The liquid should look clear to yellow and may contain tiny white or clear particles • Do not shake the carton, cartridge or on-body injector • If you have any questions on the use of the cartridge or on-body injector, speak to your doctor, pharmacist or nurse for assistance Return this medicine to the pharmacy • if the expiry date (EXP) has passed • if the liquid has ever been frozen (even if thawed) • if the cartridge or on-body injector has been dropped or damaged • if the carton perforations are broken • if the white paper tray cover is broken or missing
8
Follow the steps below each time you use Skyrizi STEP 1 – Get ready Take the carton out of the refrigerator and leave it at room temperature, out of direct sunlight, for at least 45 up to 90 minutes before injecting.
Gather all supplies and wash your hands Place the following items on a clean, flat surface.
Special disposal container
Wash and dry your hands.
Remove the white paper tray seal
9
Lift the plastic cover
Grey door
Start button
Inspect the on-body injector
Needle inside (under needle cover) STEP 2 – Set up on-body injector
10
Grey door
Fully open the grey door
Needle inside (under needle cover)
Needle cover Larger cartridge top
Inspect the cartridge
Smaller bottom tip
11
Clean the smaller bottom tip of the cartridge Locate the smaller bottom tip of the cartridge.
Smaller bottom tip
Insert straight
Clean centre of smaller bottom tip
Load the cleaned cartridge into the on-body injector
'click'
Make sure to proceed to the next step without delay after inserting the cartridge. Waiting will dry out the medicine and the on-body injector will not work afterwards.
12
Confirm cartridge is inserted and close the grey door
Do not touch the grey start button until it is time to inject. It can only be pressed one time. Proceed without delay to the next step.
Areas to inject
STEP 3 – Prepare to inject Choose and clean your injection site Choose from these 3 areas to inject:
Areas to inject
13
Small section Large section
Peel both tabs to expose skin adhesive Turn the on-body injector over to find both green pull tabs
Needle inside (under needle cover)
Activated injector Status light flashing blue
Peel away the small section using the green pull tab to expose the skin adhesive. This will remove the clear plastic strip, activating the on-body injector.
'beep-beep-beep'
If the status light flashes red and beeps, the onbody injector is not working properly. Do not continue to use it. Speak to your doctor, pharmacist or nurse for assistance. If the on-body injector is attached to your body, carefully remove it from your skin.
'beep-beep-beep-beep-beep'
14
Prepare the on-body injector for placement
15
'click' 'beep-beep-beep'
STEP 4 – Inject Skyrizi Start injection
16
Wait for the injection to finish • It may take up to 5 minutes to complete the full dose of medicine. The on-body injector will automatically stop when the injection is finished • During the injection, the status light will continue to flash green • During the injection, you will hear pumping sounds as the on-body injector continues delivering the medicine • During the injection, moderate physical activities can be done, such as walking, reaching and bending Do not continue to use the on-body injector if the status light flashes red and beeps. Carefully remove it from the skin if the status light flashes red. If this happens, speak to your doctor, pharmacist or nurse.
Injection is complete when • The on-body injector stops on its own • You hear a beep and the status light changes to solid green. If the status light has changed to solid green, this means that the injection is complete
'beep-beep-beep'
17
Remove the on-body injector • Do not remove the on-body injector if the status light is still flashing green and the injection is not finished • Do not put your fingers on the back side of the on-body injector when removing it from your skin • When the injection is done, grab the corner of the adhesive to carefully peel the on-body injector from the skin • Avoid touching the needle cover or needle on the back of the on-body injector • After removing the on-body injector, you will hear several beeps and the status light will turn off • The needle cover will cover the needle when the on-body injector is removed from the skin • It is normal to see a few small drops of liquid on your skin after removing the on-body injector • Press a cotton ball or gauze pad over the injection site on your skin and hold for 10 seconds • Do not rub the injection site • Slight bleeding at the injection site is normal
'beep-beep-beep'
Proceed to the next step.
STEP 5 – Finish Check the on-body injector Inspect the medicine window and status light. Check to see that the white plunger fills the entire medicine window and the solid green light turns off, letting you know that all the medicine has been injected. • If the white plunger does not fill the window, speak to your doctor, pharmacist or nurse
18
Special disposal container
Disposal Throw away the used on-body injector in a special disposal container straight after use. • The on-body injector contains batteries, electronics, and a needle • Leave the cartridge in the on-body injector • Do not throw away the used on-body injector in the household waste • Your doctor, pharmacist or nurse will tell you how to return the full special disposal container. There may be local guidelines for disposal
Additional information • On-body injector operating temperature range is 18°C to 28°C and relative humidity range 25% to 75% • Altitude range is minus 400 metres to 3 200 metres Glossary of symbols used on the white paper tray seal and on-body injector Symbol
Description Keep Dry Do not use if package is damaged and consult instructions for use. Single sterile barrier system Medical Device Do not reuse Manufacturer Date of Manufacture Serial Number Lot Number Reference Number Refer to instruction Manual/Booklet CE Mark Sterilised using ethylene oxide Type BF Applied Part Authorised representative in European Community/European Union
19
Skyrizi 180 mg solution for injection in cartridge comes as injection containing 180mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Skyrizi 180 mg solution for injection in cartridge is risankizumab.
This leaflet reproduces the patient information leaflet approved for Skyrizi 180 mg solution for injection in cartridge, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Crohn's disease
Risankizumab is indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.
Ulcerative colitis
Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Skyrizi is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Skyrizi is indicated.
Posology
Crohn's disease
The recommended dose is 600 mg administered by intravenous infusion at Week 0, Week 4, and Week 8, followed by 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by Week 24.
For the posology of the intravenous regimen, see section 4.2 of the Skyrizi 600 mg concentrate for solution for infusion Summary of Product Characteristics.
Ulcerative colitis
The recommended induction dose is 1200 mg administered by intravenous (IV) infusion at Week 0, Week 4, and Week 8. Starting at Week 12 and every 8 weeks thereafter, the recommended maintenance dose is based on individual patient presentation:
• A dose of 180 mg administered by subcutaneous injection is recommended for patients with adequate improvement in disease activity after induction
• A dose of 360 mg administered by subcutaneous injection is recommended for patients with inadequate improvement in disease activity after induction
Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by Week 24.
For the posology of the initial intravenous dosing regimen, see section 4.2 of the Skyrizi 600 mg concentrate for solution for infusion Summary of Product Characteristics.
Missed dose
If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time.
Special populations
Elderly
No dose adjustment is required (see section 5.2).
There is limited information in subjects aged ≥65 years.
Renal or hepatic impairment
No specific studies were conducted to assess the effect of hepatic or renal impairment on the pharmacokinetics of Skyrizi. These conditions are generally not expected to have any significant impact on the pharmacokinetics of monoclonal antibodies and no dose adjustments are considered necessary (see section 5.2).
Paediatric population
The safety and efficacy of Skyrizi for the treatment of Crohn's disease in children and adolescents younger than 16 years of age have not yet been established. The safety and efficacy of Skyrizi in children aged 0-17 years for the treatment of ulcerative colitis have not yet been established. Currently available data are described in section 5.1 and 5.2 but no recommendation on posology can be made.
Overweight patients
No dose adjustment is required (see section 5.2).
Method of administration
Skyrizi is administered by subcutaneous injection.
The injection should be administered in the thigh or abdomen. Patients should not inject into areas where the skin is tender, bruised, erythematous, indurated or damaged.
Patients may self-inject Skyrizi after training in subcutaneous injection technique with the on-body injector. Patients should be instructed to read section 7 'Instructions for use' provided in the package leaflet before administration.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Clinically important active infections (e.g. active tuberculosis, see section 4.4).
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Infections
Risankizumab may increase the risk of infection.
In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.
Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.
Tuberculosis
Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.
Immunisations
Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment (see section 5.2).
Hypersensitivity
Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab (see section 4.8). If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.
Excipients with known effect
Polysorbate
This medicinal product contains 0.24 mg of polysorbate 20 in each 180 mg dose and 0.48 mg of polysorbate 20 in each 360 mg dose. Polysorbates may cause allergic reactions.
Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per cartridge, that is to say essentially 'sodium‑free'.
Risankizumab is not expected to undergo metabolism by hepatic enzymes or renal elimination. Interactions between risankizumab and inhibitors, inducers, or substrates of medicinal product metabolising enzymes are not expected and no dose adjustment is needed (see section 5.2).
Concomitant immunosuppressive therapy
The safety and efficacy of risankizumab in combination with immunosuppressants, including biologics, have not been evaluated.
Women of childbearing potential
Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment.
Pregnancy
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of risankizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of risankizumab during pregnancy.
Breast-feeding
It is unknown whether risankizumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which decreases to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period. A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.
Fertility
The effect of risankizumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility.
Risankizumab has no or negligible influence on the ability to drive and use machines.
Summary of the safety profile
The most frequently reported adverse reactions were upper respiratory infections (15.6% in Crohn's disease and 26.2% in ulcerative colitis).
Tabulated list of adverse reactions
Adverse reactions for risankizumab from clinical studies (Table 1) are listed by MedDRA system organ class and are based on the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); and very rare (< 1/10 000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Table 1: List of adverse reactions
System Organ Class
Frequency
Adverse reactions
Infections and infestations
Very common
Upper respiratory infectionsa
Common
Tinea infectionsb
Uncommon
Folliculitis
Nervous system disorders
Common
Headachec
Skin and subcutaneous tissue disorders
Common
Pruritus
Rash
Eczema
Uncommon
Urticaria
General disorders and administration site conditions
Common
Fatigued
Injection site reactionse
Immune system disorders
Rare
Anaphylactic reactions
a Includes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis (including viral), tonsillitis, laryngitis, peritonsillar abscess
b Includes: tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, onychomycosis, tinea infection
c Includes: headache, tension headache, sinus headache
d Includes: fatigue, asthenia, malaise
e Includes: injection site bruising, erythema, haematoma, haemorrhage, irritation, pain, pruritus, reaction, swelling, induration, hypersensitivity, nodule, rash, urticaria, vesicles, warmth; infusion site erythema, extravasation, reaction, swelling
Description of selected adverse reactions
Psoriasis
Infections
Over the entire psoriasis programme including long-term exposure to risankizumab, the rate of infections was 75.5 events per 100 subject-years. The majority of cases were non-serious and mild to moderate in severity and did not lead to discontinuation of risankizumab. The rate of serious infections was 1.7 events per 100 subject-years (see section 4.4).
Crohn's disease
The adverse drug reaction profile observed in patients with Crohn's disease treated with risankizumab was consistent with the adverse drug reaction profile observed in patients across indications. No new adverse reactions were identified in risankizumab Crohn's disease studies.
Infections
The majority of infections were non‑serious and mild to moderate in severity and did not lead to discontinuation of risankizumab.
The rate of infections in the pooled data from the 12-week induction studies was 83.3 events per 100 subject‑years in subjects treated with risankizumab 600 mg IV compared to 117.7 events per 100 subject‑years in placebo. The rate of serious infections was 3.4 events per 100 subject-years in subjects treated with risankizumab 600 mg IV compared to 16.7 events per 100 subject-years in placebo (see section 4.4).
The rate of infections in the 52‑week maintenance study was 57.7 events per 100 subject-years in subjects treated with risankizumab 360 mg SC after risankizumab induction compared to 76.0 events per 100 subject‑years in subjects who received placebo after risankizumab induction. The rate of serious infections was 6.0 events per 100 subject-years in subjects treated with risankizumab 360 mg SC after risankizumab induction compared to 5.0 events per 100 subject‑years in subjects who received placebo after risankizumab induction (see section 4.4).
Ulcerative colitis
Overall, the safety profile observed in patients with ulcerative colitis treated with risankizumab was consistent with the safety profile observed in patients across indications.
Infections
The rate of infections in the pooled data from the 12-week induction study was 78.3 events per 100 subject‑years in subjects treated with risankizumab 1 200 mg intravenously compared to 74.2 events per 100 subject‑years in placebo. The rate of serious infections was 3.0 events per 100 subject-years in subjects treated with risankizumab 1 200 mg intravenously compared to 5.4 events per 100 subject‑years in placebo (see section 4.4).
The rate of infections in the 52-week maintenance study was 67.4 events per 100 subject‑years in subjects treated with risankizumab 180 mg subcutaneously and 56.5 events per 100 subject‑years in subjects treated with risankizumab 360 mg subcutaneously after risankizumab induction compared to 64.6 events per 100 subject‑years in subjects who received placebo after risankizumab induction. The rate of serious infections was 1.1 events per 100 subject-years in subjects treated with risankizumab 180 mg subcutaneously and 0.6 events per 100 subject-years in subjects treated with risankizumab 360 mg subcutaneously after risankizumab induction compared to 2.3 events per 100 subject‑years in subjects who received placebo after risankizumab induction (see section 4.4).
Immunogenicity
As with all therapeutic proteins, there is the potential for immunogenicity with risankizumab. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
For subjects with Crohn's disease treated with risankizumab at the recommended IV induction and SC maintenance doses for up to 64 weeks in CD clinical trials, treatment-emergent anti-drug antibodies and neutralizing antibodies were detected in 3.4% (2/58) and 0% (0/58) of evaluated subjects, respectively.
For subjects with ulcerative colitis treated with risankizumab at the recommended intravenous induction and subcutaneous maintenance doses (180 mg or 360 mg) for up to 64 weeks in ulcerative colitis clinical trials, treatment-emergent anti-drug antibodies and neutralizing antibodies were detected in 8.9% (8/90) and 6.7% (6/90) for the 180 mg SC dose, or 4.4% (4/91) and 2.2% (2/91) for the 360 mg SC dose, of evaluated subjects, respectively.
Antibodies to risankizumab including neutralizing antibodies were not associated with changes in clinical response or safety.
Elderly
There is limited safety information in subjects aged ≥65 years.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme:
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Skyrizi 180 mg solution for injection in cartridge. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.